VOYA Investment Management’s Protagonist Therapeutics PTGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$47.9M Buy
454,383
+88,218
+24% +$7.81M 0.05% 292
2025
Q4
$32M Buy
366,165
+60,746
+20% +$4.97M 0.03% 403
2025
Q3
$20.3M Buy
305,419
+25,065
+9% +$1.42M 0.02% 493
2025
Q2
$15.5M Buy
280,354
+220,676
+370% +$10.6M 0.02% 604
2025
Q1
$2.89M Sell
59,678
-22,949
-28% -$962K ﹤0.01% 1153
2024
Q4
$3.19M Sell
82,627
-31,225
-27% -$1.36M ﹤0.01% 1119
2024
Q3
$5.12M Buy
113,852
+48,786
+75% +$1.97M 0.01% 986
2024
Q2
$2.25M Sell
65,066
-4,377
-6% -$128K ﹤0.01% 1278
2024
Q1
$2.01M Buy
69,443
+26,198
+61% +$713K ﹤0.01% 1347
2023
Q4
$992K Buy
43,245
+282
+0.7% +$4.93K ﹤0.01% 1683
2023
Q3
$717K Buy
42,963
+1,374
+3% +$26.7K ﹤0.01% 1847
2023
Q2
$1.15M Sell
41,589
-52,468
-56% -$1.31M ﹤0.01% 1589
2023
Q1
$2.16M Sell
94,057
-45,342
-33% -$761K ﹤0.01% 1328
2022
Q4
$1.52M Sell
139,399
-7,060
-5% -$59.6K ﹤0.01% 1446
2022
Q3
$1.23M Buy
146,459
+129,091
+743% +$1.22M ﹤0.01% 1523
2022
Q2
$137K Hold
17,368
﹤0.01% 2542
2022
Q1
$411K Hold
17,368
﹤0.01% 2015
2021
Q4
$594K Sell
17,368
-69
-0.4% -$2.18K ﹤0.01% 1900
2021
Q3
$309K Buy
17,437
+1,187
+7% +$50.6K ﹤0.01% 2334
2021
Q2
$729K Buy
16,250
+1,156
+8% +$38.2K ﹤0.01% 1860
2021
Q1
$391K Buy
15,094
+2,023
+15% +$51.2K ﹤0.01% 2164
2020
Q4
$264K Buy
13,071
+3,045
+30% +$65.5K ﹤0.01% 2264
2020
Q3
$196K Buy
+10,026
New +$188K ﹤0.01% 2163

Other funds holding PTGX

VOYA Investment Management's PTGX Position: Q1 2026 in Review

VOYA Investment Management increased its Protagonist Therapeutics (PTGX) stake by 24% in Q1 2026, buying an estimated $7.81M and bringing the position to 454,383 shares worth $47.9M. The position accounts for 0.05% of the portfolio, ranked #292.

VOYA Investment Management first reported a position in PTGX in Q3 2020 and has held it in 23 quarters since. 318 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • VOYA Investment Management held 454,383 shares of Protagonist Therapeutics worth $47.9M as of Q1 2026.
  • VOYA Investment Management bought 88,218 Protagonist Therapeutics shares in Q1 2026, an estimated $7.81M.
  • Protagonist Therapeutics made up 0.05% of VOYA Investment Management's portfolio in Q1 2026, its #292 holding.
  • VOYA Investment Management first reported a position in Protagonist Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • 318 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on VOYA Investment Management's 13F filing for Q1 2026, filed 12 May 2026.